Robust evidence for fenofibrate in patients with metabolic syndrome on statins
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Robust evidence for fenofibrate in patients with metabolic syndrome on statins
05 Feb 2024